Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the composite of
heart failure (HF) hospitalizations or cardiovascular mortality among patients with HF …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …

Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …

Background: Frailty is a multidimensional condition often diagnosed in older adults with
hypertension and diabetes, and both these conditions are associated with endothelial …

Aims The aim of this study was to examine the effect of dapagliflozin on the incidence of
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …

Objectives The goal of this study was to evaluate the effect of empagliflozin, in addition to
optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis …

Abstract Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …

Many patients with symptoms and signs of heart failure have a left ventricular ejection
fraction≥ 50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a …

Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …